Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

Novartis building

Novartis plans filings for acromegaly candidate

Could add to Signifor’s indications

- PMLiVE

Novartis teams up with artist in meningitis campaign

Digital book contains photos of disease survivors taken by Anne Geddes

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

- PMLiVE

New Novartis MS app will turn up the heat on its rivals

Patients can use SymTrac iPhone app to track symptoms and relapses on their current treatment

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

- PMLiVE

Lilly’s stomach cancer drug cleared by FDA

Cyramza is tipped to reach blockbuster status depending on approvals

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

Changing the guard at Novartis’ Sandoz and Alcon units

Richard Francis joins from Biogen Idec and Kevin Buehler retires

- PMLiVE

UK cancer awards programme launches

QiC Oncology 2014  announced at ABPI Annual Conference

Novartis building

Novartis replaces execs in Japan after investigation

Finds irregular practices in clinical trials programme

- PMLiVE

Glioblastomas – a personalised future?

Despite some recent advances treatment remains palliative

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links